Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Grand House Mulia Tbk. (HOMI) vs Brigit Biofarmaka Teknologi Tbk. (OBAT) Price & Performance

Grand House Mulia Tbk.Trade
Brigit Biofarmaka Teknologi Tbk.Trade

Price performance (Past 24H)

Key statistics

Grand House Mulia Tbk. vs Brigit Biofarmaka Teknologi Tbk. — how do they compare? Grand House Mulia Tbk. trades at Rp232 (market cap 384.3B, 3.49M 24h volume), while Brigit Biofarmaka Teknologi Tbk. trades at Rp240 (market cap 166.01B, 324K 24h volume). The key difference: Grand House Mulia Tbk. is far larger — about 2.3× Brigit Biofarmaka Teknologi Tbk.'s market cap, and Grand House Mulia Tbk. is more actively traded (3.49M versus 324K). Which is the better fit depends on your goals.

HOMIOBAT
Market Cap
384.3B166.01B
Volume
3.49M324K
Lot
34.89K3.24K
Turnover
796.11M77.68M
Average Price
228.18239.75
Value
796.11M77.68M
Indicative Equilibrium Price
232240
Indicative Equilibrium Volume
1101

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

HOMI
View details
OBAT
View details

About Grand House Mulia Tbk.

PT Grand House Mulia, Tbk (“the Company”) was established in Republic of Indonesia based on the Notarial Deed No. 1 dated January 9, 2006 of Suryati Moerwibowo, S.H., The Company has commercially operated in April 2019.

Read more on HOMI

About Brigit Biofarmaka Teknologi Tbk.

PT. Brigit Biofarmaka Teknologi Tbk. (the Company) was established based on Notarial Deed No. 103 dated December 14, 2015 of Yoerista Arya Megasari, S.H., M.Kn., Notary in Sukoharjo. The company starts production commercially in 2018.

Read more on OBAT